United Therapeutics CEO Rothblatt sells $5 million in shares By Investing.com

Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (), sold common stock worth approximately $5,038,970 on July 27, 2026, according to a recent Form 4 filing with the Securities and Exchange Commission. The transactions also involved the exercise of stock options.

The sales encompassed 9,500 shares of common stock, executed at prices ranging from $525.8111 to $535.04 per share. These shares were held indirectly through family trusts where Ms. Rothblatt shares investment power. The timing of the sale comes after United Therapeutics shares delivered a remarkable 77% return over the past year, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. For investors seeking deeper insights, InvestingPro offers exclusive tips on UTHR’s financial health and a comprehensive Pro Research Report, part of coverage on over 1,400 US equities.

Concurrently with the sales, Ms. Rothblatt exercised options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $135.42 per share. This acquisition represented a total value of approximately $1,286,489. These options were also held indirectly through a family trust.

All reported transactions, including both the option exercise and the subsequent sale of the resulting shares, were carried out under a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is set to continue until either 1,734,410 stock options are exercised (all expiring on March 15, 2027) or December 31, 2026, whichever comes first.

Following these transactions, Ms. Rothblatt indirectly holds 324,443 shares of common stock through various family trusts. Additionally, 265,410 stock options remain beneficially owned indirectly through a family trust.

In other recent news, United Therapeutics Corporation received premarket approval from the U.S. Food and Drug Administration for its LungFX lung perfusion device. This device is designed to assess donor lungs outside the body after procurement and before transplantation. Additionally, TD Cowen reiterated its Buy rating on United Therapeutics stock, setting a price target of $675.00. The firm hosted an investor lunch featuring a leading pulmonologist involved in the TETON studies. Meanwhile, BETA Technologies completed the first electric aircraft flights under the Federal Aviation Administration’s eVTOL Integration Pilot Program. These flights spanned approximately 275 nautical miles across Virginia and Maryland in collaboration with local aviation authorities. In the biopharmaceutical sector, Raymond James anticipates that Insmed might surpass 2026 earnings consensus due to favorable Symphony data tracking. The narrowing gap between sell-side and buy-side expectations is seen as a potential driver for sequential launch growth. These developments highlight significant advancements and analyst insights across various industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.